Valuation: Voyager Therapeutics, Inc.

Market Cap 108M 96.78M 89.36M 81.03M 151M 10.24B 153M 1.07B 425M 5.37B 405M 396M 17.02B P/E 2026 *
-1.04x
P/E 2027 * -1.39x
Enterprise Value -10.47M -9.4M -8.68M -7.87M -14.7M -994M -14.88M -104M -41.31M -521M -39.3M -38.46M -1.65B EV / Sales 2026 *
-0.52x
EV / Sales 2027 * -0.62x
Free-Float
85.16%
Yield 2026 *
-
Yield 2027 * -
1 day-1.14%
1 week-21.00%
Current month-35.45%
1 month-35.93%
3 months-44.01%
6 months-53.99%
Current year-55.98%
1 week 1.71
Extreme 1.71
2.16
1 month 1.71
Extreme 1.71
2.75
Current year 1.71
Extreme 1.71
5.48
1 year 1.71
Extreme 1.71
5.48
3 years 1.71
Extreme 1.71
11.72
5 years 1.71
Extreme 1.71
14.34
10 years 1.71
Extreme 1.71
31.91
Manager TitleAgeSince
Chief Executive Officer 68 2022-03-21
Director of Finance/CFO 56 2026-04-30
Chief Tech/Sci/R&D Officer 56 2018-10-31
Director TitleAgeSince
Director/Board Member 71 2013-12-31
Director/Board Member 73 2015-09-16
Director/Board Member 70 2017-01-04
Date Insider Type Main position Quantity % Market Cap. Importance
6/9/26 Free

Chairman

30,000 0.0497%
6/9/26 Free

Director

30,000 0.0497%
5/8/26 Other

Controller/Auditor

115,249 0.1911%
Change 5-day change 1-year change 3-year change Capi.($)
-1.14%-21.00%-64.03%-73.01% 108M
-3.10%-3.43%+36.29%+67.69% 65.28B
+0.33%+7.26%+11.51%+77.95% 54.57B
+0.16%+1.73%+9.89%+102.10% 53.59B
-0.75%+1.38%+24.89%+50.91% 45.03B
-1.30%-4.80%+16.05%+114.76% 42.17B
+1.26%-5.26%+221.12%+900.64% 39.42B
-0.74%-4.84%+14.53%+44.45% 32.71B
-2.70%-7.34%+23.17%+0.36% 24.01B
+1.11%+15.18%+60.27%+49.33% 26.5B
Average -0.70%+0.32%+35.37%+133.52% 38.34B
Weighted average by Cap. -0.73%+1.71%+43.46%+155.30%

Financials

2026 *2027 *
Net sales 20.28M 18.2M 16.8M 15.24M 28.48M 1.93B 28.83M 201M 80.01M 1.01B 76.11M 74.48M 3.2B 46.58M 41.81M 38.6M 35.01M 65.43M 4.42B 66.23M 463M 184M 2.32B 175M 171M 7.35B
Net income -106M -95.27M -87.97M -79.77M -149M -10.08B -151M -1.05B -419M -5.29B -398M -390M -16.76B -88.66M -79.58M -73.48M -66.63M -125M -8.42B -126M -881M -350M -4.41B -333M -326M -14B
Net Debt -118M -106M -98.04M -88.9M -166M -11.24B -168M -1.18B -467M -5.89B -444M -435M -18.68B -136M -123M -113M -103M -192M -12.97B -194M -1.36B -539M -6.8B -512M -501M -21.55B
Projected Income Statement - Annual - Voyager Therapeutics, Inc.
Logo Voyager Therapeutics, Inc.
Voyager Therapeutics, Inc. is a biotechnology company engaged in leveraging the power of human genetics to modify the course of neurological diseases. The Company’s pipeline includes programs for Alzheimer’s disease, Friedreich’s ataxia, Parkinson’s disease, amyotrophic lateral sclerosis (ALS), and multiple other diseases of the central nervous system. Many of its programs are derived from its Tropism Redirection of AAV by Cell-type-specific Expression of RNA (TRACER) adeno-associated virus (AAV) capsid discovery platform, which is used to generate capsids and identify associated receptors to potentially enable high brain penetration with genetic medicines following intravenous dosing. Its pipeline of programs includes Anti-Tau Antibody (VY7523), Tau Silencing Gene Therapy (VY1706), SOD1 Silencing Gene Therapy Program, Vectorized Anti-Amyloid Antibody Early Research Program, Friedreich’s Ataxia Program: VY-FXN01, GBA1 Gene Replacement Program, HD Program and others.
Employees
141
Date Price Change Volume
26-10-27 US$1.730 -1.14% 1,268,485
26-10-26 US$1.750 +0.57% 1,662,209
26-10-23 US$1.740 -6.45% 1,052,312
26-10-22 US$1.860 -7.92% 1,299,711
26-10-21 US$2.020 -7.76% 935,815
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
MarketScreener Ratings - Voyager Therapeutics, Inc.
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
11
Last Close Price
1.750USD
Average target price
14.89USD
Spread / Average Target
+750.79%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - Voyager Therapeutics, Inc.
  1. Stock Market
  2. Stocks
  3. VYGR Stock